CALCA and migraine disorder: In a 24-week clinical trial of eptinezumab for migraine prevention, the incidence of COVID-19, recorded as treatment-emergent adverse events, was also similar between treatment (6.2%) and placebo (5.4%) groups.21 Our study did not find a significant difference in the incidence of COVID-19 between patients receiving or not receiving CGRP mAbs (7.4 vs 6.9 cases per 1000 person-months), suggesting that CGRP mAbs may be used among patients who are at risk of or have COVID-19.